1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
LabGenomics Co., Ltd.

LabGenomics Co., Ltd.

084650.KQ
LabGenomics Co., Ltd.KR flagKOSDAQ
654.00
KRW
-43.00
- -
48.55BMarket Cap

Total Valuation

LabGenomics Co., Ltd. carries a market capitalization of 48.55B, placing it among publicly traded companies globally. Its enterprise value stands at 103.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap48.55B
Enterprise Value103.58B

Share Statistics

LabGenomics Co., Ltd. currently has 74.24M shares outstanding.

Shares Outstanding74.24M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 1.14, and the price-to-book ratio stands at 0.84.

PE RatioN/A
PS Ratio1.14
PB Ratio0.84
P/TBV Ratio1.35
P/FCF Ratio-3.59
P/OCF Ratio-3.37

Enterprise Valuation

EV / Sales1.23
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

LabGenomics Co., Ltd. maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.21, indicating elevated leverage, while an interest coverage ratio of -8.78 demonstrates limited ability to service its debt obligations.

Current Ratio1.17
Quick Ratio0.88
Debt / Equity41.21
Debt / EBITDA-1.18
Interest Coverage-8.78

Financial Efficiency

Return on Equity (ROE)-43.47
Return on Assets (ROA)-24.33
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover18.07

Taxes

Income Tax4.81B
Effective Tax RateN/A

Stock Price Statistics

LabGenomics Co., Ltd.'s stock has declined approximately -72.17021% over the past 52 weeks. The 50-day moving average sits at 1,112.18, while the 200-day moving average is 1,682.82.

Beta (5Y)N/A
52-Week Price Change-72.17021%
50-Day Moving Average1,112.18
200-Day Moving Average1,682.82
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, LabGenomics Co., Ltd. generated 84.19B in revenue and converted that into -63.71B in net income, yielding earnings per share of -856.22. EBITDA reached -51.98B, while operating income came in at -51.98B.

Revenue84.19B
Gross Profit28.91B
Operating Income-51.98B
Pretax Income-58.90B
Net Income-63.71B
EBITDA-51.98B
EBIT-51.98B
Earnings Per Share (EPS)-856.22

Balance Sheet

LabGenomics Co., Ltd. holds 53.87B in cash and equivalents against 61.47B in total debt, resulting in a net debt position of 49.98B. Total book value stands at 114.71B, with working capital of 10.43B providing operational flexibility.

Cash & Cash Equivalents53.87B
Total Debt61.47B
Net Debt49.98B
Equity (Book Value)114.71B
Book Value Per Share1,541.73
Working Capital10.43B

Cash Flow

LabGenomics Co., Ltd. produced -28.49B in operating cash flow over the past twelve months. After subtracting -1.79B in capital expenditures, free cash flow totaled -30.29B - equivalent to -407.07 per share.

Operating Cash Flow-28.49B
Capital Expenditures-1.79B
Free Cash Flow-30.29B
FCF Per Share-407.07

Margins

LabGenomics Co., Ltd. operates with a gross margin of 34.33, reflecting its pricing power and cost economics. The operating margin of -61.74 and net profit margin of -75.67 provide insight into operational efficiency.

Gross Margin34.33
Operating Margin-61.74
Pretax Margin-69.96
Profit Margin-75.67
EBITDA Margin-61.74

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-2.30
FCF Yield-27.82

Stock Splits

LabGenomics Co., Ltd.'s most recent stock split took place on August 7, 2023 with a 1:2 split ratio.

Last Split Date8/7/2023
Split Ratio1:2

Scores

LabGenomics Co., Ltd. posts an Altman Z-Score of 0.89, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.89